Moreover, MEK/ERK inhibitor treatment enhanced PRED-induced cell death suggesting that reintroducing synthetic miR-335 and overriding MAPK1 activity and MEK/ERK pathway inhibition could provide a basis for the development of further therapeutic strategies to overcome PRED resistance and so improve treatment outcome in ALL patients [42]. The gene discussed is MAPK1; the disease is acute lymphoblastic leukemia.